At a glance
ClinicalIndex Comparison RecordN/ACompleted· 692 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the "New Drug Re-Examination"
In Brief
An observational study for Tourette's Disorder. Completed, enrolled 692 participants across 4 sites.
Detailed Summary
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTourette's Disorder
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedFeb 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedFeb 20, 2013
Enrollment StartJun 1, 2012
Primary CompletionMay 29, 2015
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 13.4 years ago